Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC's MedImmune Announces Agreement With Progenics Pharmaceuticals, Inc. To Develop Therapies Against Serious Bacterial Infections


Monday, 17 Dec 2012 09:00am EST 

MedImmune, the global biologics arm of AstraZeneca PLC, announced that it has signed an in-licensing agreement with Progenics Pharmaceuticals, Inc. for Progenics' Clostridium difficile late-stage preclinical program. The agreement was led by MedImmune's Infectious Diseases & Vaccines Innovative Medicines (iMed) Unit. Financial details of the agreement were not disclosed. 

Company Quote

4780.0
59.5 +1.26%
28 Nov 2014